Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism

Table 1

Patient general characteristics.

Gender ( )
Male, (%)	133 (45.4)
Female, (%)	160 (54.6)
Age (years,)
Median (range)	59.9 (22-89)
Age at diagnosis (years,)
Median (range)	56.5 (15^‡-87)
Race ( )
Caucasian, (%)	285 (97.3)
African, (%)	1 (0.3)
Other or not specified, (%)	7 (2.4)
Type of diagnosis ()
Histopathological, (%)	254 (86.7)
Cytological, (%)	17 (5.8)
Biochemical, (%)	5 (1.7)
Other or not specified, (%)	17 (5.8)
Primary tumour by localization ()
Pancreas, (%)	91 (31.1)
Head, (%)	28 (30.7)
Body, (%)	29 (31.9)
Tail, (%)	32 (35.2)
Not specified, (%)	2 (2.2)
Jejunum-ileum, (%)	71 (24.2)
Stomach, (%)	40 (13.7)
Type 1, (%)	23 (57.5)
Type 2, (%)	9 (22.5)
Type 3, (%)	7 (17.5)
Not specified, (%)	1 (2.5)
Rectum, (%)	25 (8.5)
Duodenum, (%)	20 (6.8)
Appendix, (%)	20 (6.8)
Colon, (%)	16 (5.5)
Oesophagus, (%)	3 (1.0)
Unknown primary tumour	7 (2.4)
Tumour group by secretion
Carcinoid syndrome, positive/total studied (%)	17/115 (14.8)
Gastrinoma^$, positive/total studied^$$ (%)	4/55 (7.3)
Insulinoma^&, positive/total studied^&& (%)	11/24 (45.8)
Tumour group by grade (); WHO, 2010
NET G1, (%)	158 (64.0)
NET G2, (%)	61 (24.7)
NEC, (%)	28 (11.3)
Tumour group by stage (); TNM (ENETS)
Localized, (%)	76 (35.5)
Locoregional, (%)	43 (20.1)
Disseminated, (%)	95 (44.4)

^‡Patient was 15 y old at diagnosis, currently 22 y old at the time of the study; carcinoid syndrome criteria: times the normal value and flushing and/or diarrhea; cases with 5-HIAA quantification; ^$gastrinoma criteria: times the normal value and exclusion of types I and II gastric tumours; ^$$cases with gastrin quantification; ^&insulinoma criteria: hypoglycemic symptoms, Whipple triad, and/or positive 72-hour prolonged fasting test; ^$$cases with insulin quantification.